system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, OBJECTIVE, METHODS, RESULTS. Meshes: Cafe-au-Lait Spots, Child, Child, Preschool, Chromogranins, Female, Fibrous Dysplasia of Bone, Fibrous Dysplasia, Polyostotic, GTP-Binding Protein alpha Subunits, Gs, Genetic Testing, Humans, Infant, Infant, Newborn, Leukocytes, Phenotype, Polymerase Chain Reaction, Puberty, Precocious, Severity of Illness Index.
user
Is gNAS mutation detection related to disease severity in girls with McCune-Albright syndrome and precocious puberty? Context: McCune-Albright syndrome (MAS) is characterized by a triad of gonadotropin-independent precocious puberty, café au lait skin pigmentation and fibrous dysplasia of bone. MAS is due to activating mutations of GNAS, the gene encoding Gsalpha. Interest exists in the use of GNAS mutation analysis to make a definitive diagnosis when the phenotype is not diagnostic, i.e. in partial forms of MAS. The utility of using peripheral blood for mutation analysis in this setting has not been thoroughly evaluated. We performed a systematic analysis of genomic DNA for the detection of GNAS activating mutations in girls with MAS who presented with precocious puberty to evaluate whether identification of an activating mutation in peripheral blood is related to the presence of other features of MAS. Genomic DNA was isolated from blood from 13 girls with gonadotropin-independent precocious puberty. A polymerase chain reaction (PCR)-based technique was performed for GNAS mutation identification. GNAS activating mutations were identified in 4 patients, all of whom had classic MAS based on clinical evidence.
assistant
Detection of activating mutations in leukocyte genomic DNA extracted from peripheral blood samples from girls with gonadotropin-independent precocious puberty was associated with the presence of other phenotypic manifestations of MAS. Until improvements in the diagnostic utility of GNAS activating mutation analysis from leukocyte genomic DNA occur, such testing in patients with atypical forms of MAS should continue to be reserved for research settings. Final Decision: yes